Swiss National Bank raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 538,045 shares of the life sciences company’s stock after acquiring an additional 3,600 shares during the period. Swiss National Bank owned approximately 368,523.97% of Illumina worth $107,179,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Illumina by 2.6% in the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after acquiring an additional 255,498 shares during the last quarter. Capital World Investors grew its stake in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after acquiring an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC grew its stake in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Winslow Capital Management LLC purchased a new stake in shares of Illumina in the second quarter worth $211,584,000. Finally, HPM Partners LLC lifted its holdings in shares of Illumina by 29,103.8% during the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after purchasing an additional 749,424 shares in the last quarter. 93.07% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts have recently issued reports on the company. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Citigroup Inc. upped their price target on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Barclays PLC upped their price target on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Bank of America Corporation upped their price target on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $205.00 price target (up from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the stock. Illumina currently has an average rating of “Hold” and an average price target of $200.88.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at $208.94 on Friday. Illumina, Inc. has a one year low of $119.37 and a one year high of $214.50. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $30,603.06, a P/E ratio of 61.29, a P/E/G ratio of 3.46 and a beta of 0.74.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 EPS. analysts anticipate that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.
In other news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $205.71, for a total value of $29,827.95. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $194.73, for a total value of $3,894,600.00. Following the completion of the transaction, the director now owns 539,176 shares in the company, valued at $104,993,742.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 187,964 shares of company stock valued at $38,454,069. 1.60% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2017/11/11/swiss-national-bank-buys-3600-shares-of-illumina-inc-ilmn.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.